Evidence map›Paper›PMID 23639351›Full record

ArticleCellular immunology2013

Hypoxia and cytoplasmic alkalinization upregulate growth hormone expression in lymphocytes.

Douglas A Weigent

Abstract read
In one paragraph

Article in Cellular immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Optical Control of CD8Frontiers in immunology · 2021
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Douglas A WeigentDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL 35294-0005, USA. Weigent@uab.edu
University of Alabama at Birmingham · US

Funding

PRODUCTION AND FUNCTION OF GHRH IN THE IMMUNE SYSTEMR01AI041651 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WEIGENT, DOUGLAS A · 1997 to 2003
$731k
NIAID NIH HHS R01 AI041651
6 · The paper itself

Abstract

We report here that culture of lymphoid cells under hypoxic conditions showed an increase in both luciferase expression from a GH-promoter luciferase construct and the levels of lymphocyte GH. The effect was mimicked by treatment of cells with cobalt chloride consistent with a specific oxygen-sensing mechanism. We identified a putative hypoxia response element (HRE) in the GH promoter at the region -176 bp to -172 bp that contains a copy of the hypoxia-inducible factor-1 (Hif-1) binding motif (5'-ACGTG-3'). The results also showed that culture of primary rat spleen cells with different doses of TMA induced a dose-dependent increase in lymphocyte GH by Western blot analysis. Greater levels of GH are induced in T cell-enriched populations compared to B cell-enriched populations after treatment with CoCl(2) or TMA. Our results suggest that the stressful cellular conditions likely to occur at sites of inflammation or tumor growth may induce the synthesis of lymphocyte GH.

Indexed as

Gene ExpressionUp-RegulationAlkaliesAnimalsBase SequenceBlotting, WesternCell HypoxiaCell Line, TumorCells, CulturedCobaltCytoplasmDose-Response Relationship, DrugGrowth HormoneHydrogen-Ion ConcentrationHypoxia-Inducible Factor 1LuciferasesAlkaliesCobaltcobaltous chlorideGrowth HormoneHypoxia-Inducible Factor 1Luciferases

Identifiers

PMID23639351
PMCPMC3693391
OpenAlexW2082564126

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.